KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Short-Term Debt issuances (2016 - 2025)

Pfizer (PFE) has disclosed Short-Term Debt issuances for 17 consecutive years, with $101.0 million as the latest value for Q4 2025.

  • Quarterly Short-Term Debt issuances changed N/A to $101.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$796.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$796.0 million for FY2025, 69.27% up from the prior year.
  • Short-Term Debt issuances for Q4 2025 was $101.0 million at Pfizer, up from $6.0 million in the prior quarter.
  • The five-year high for Short-Term Debt issuances was $4.5 billion in Q4 2023, with the low at -$2.6 billion in Q3 2024.
  • Average Short-Term Debt issuances over 5 years is $85.8 million, with a median of $6.0 million recorded in 2025.
  • The sharpest move saw Short-Term Debt issuances skyrocketed 2296.0% in 2022, then plummeted 32275.0% in 2024.
  • Over 5 years, Short-Term Debt issuances stood at $25.0 million in 2021, then soared by 3380.0% to $870.0 million in 2022, then surged by 418.51% to $4.5 billion in 2023, then crashed by 157.42% to -$2.6 billion in 2024, then surged by 103.9% to $101.0 million in 2025.
  • According to Business Quant data, Short-Term Debt issuances over the past three periods came in at $101.0 million, $6.0 million, and -$903.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.